• University of Pennsylvania Featured PhD Programmes
  • FindA University Ltd Featured PhD Programmes
  • Aberdeen University Featured PhD Programmes
  • Staffordshire University Featured PhD Programmes
  • University of Tasmania Featured PhD Programmes
  • University of Cambridge Featured PhD Programmes
University of York Featured PhD Programmes
University of Liverpool Featured PhD Programmes
Norwich Research Park Featured PhD Programmes
Imperial College London Featured PhD Programmes
University of Reading Featured PhD Programmes

The mechanism and intervention of renal injury

This project is no longer listed in the FindAPhD
database and may not be available.

Click here to search the FindAPhD database
for PhD studentship opportunities
  • Full or part time
    Dr Yang
    Prof Brunskill
  • Application Deadline
    Applications accepted all year round
  • Self-Funded PhD Students Only
    Self-Funded PhD Students Only

Project Description

Acute kidney injury (AKI) has high mortality and could progress to chronic kidney disease (CKD). The ischemia/reperfusion injury (IRI) is one of the main courses of AKI. The mechanism of AKI has not been fully understood and there is lack of effective diagnosis and treatment. Autophagy recently attracted significant attention in AKI, while properdin, a positive regulator of alternative pathway of complement activation, may also play crucial roles.
We demonstrated apoptosis and inflammation with up-regulated caspase-3 in AKI, whereas small interfering RNA (siRNA) targeting caspase-3 protected tubular cells/kidneys. Latterly, we also showed a novel erythropoietin derived peptide (CHBP) without erythropoiesis improved AKI via inhibiting caspase-3, apoptosis and inflammation. Modern technologies such as microarray enable simultaneously investigating hundreds of thousands of genes. We have evaluated gene expression profile in human renal allograft biopsies and subsequently developed an analytic regime.
In the proposed project, both wild-type and properdin knockout mice subjected to renal IRI will be used to explore multiple pathways involved in AKI and intervention such as using CHBP and caspase-3 siRNA, focusing on immunity, inflammation, autophagy, apoptosis and fibrosis. Most importantly, new combinational biomarkers will be also defined and validated for timely diagnosis and precise personal treatment to prevent CKD.


We are an equal opportunities employer and particularly welcome applications for Ph.D. places from women, minority ethnic and other under-represented groups.

How good is research at University of Leicester in Clinical Medicine?

FTE Category A staff submitted: 72.10

Research output data provided by the Research Excellence Framework (REF)

Click here to see the results for all UK universities
Share this page:

Cookie Policy    X